Literature DB >> 20921447

Letter by Gurbel et al regarding article, "Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement".

Paul A Gurbel, Udaya S Tantry, Alan R Shuldiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20921447     DOI： 10.1161/CIRCULATIONAHA.110.943548

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  7 in total

Review 1.  The clinical relevance of the clopidogrel-proton pump inhibitor interaction.

Authors:  Atif Mohammad; Emmanouil S Brilakis; Rick A Weideman; Bertis B Little; Subhash Banerjee
Journal:  J Cardiovasc Transl Res       Date:  2012-02-14       Impact factor: 4.132

2.  The CYP2C19*17 variant is not independently associated with clopidogrel response.

Authors:  J P Lewis; S H Stephens; R B Horenstein; J R O'Connell; K Ryan; C J Peer; W D Figg; S D Spencer; M A Pacanowski; B D Mitchell; A R Shuldiner
Journal:  J Thromb Haemost       Date:  2013-09       Impact factor: 5.824

3.  Pharmacogenomics: application to the management of cardiovascular disease.

Authors:  J A Johnson; L H Cavallari; A L Beitelshees; J P Lewis; A R Shuldiner; D M Roden
Journal:  Clin Pharmacol Ther       Date:  2011-09-14       Impact factor: 6.875

Review 4.  Pharmacogenomics of anti-platelet and anti-coagulation therapy.

Authors:  Adam S Fisch; Christina G Perry; Sarah H Stephens; Richard B Horenstein; Alan R Shuldiner
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

Review 5.  Cardiovascular pharmacogenomics.

Authors:  Dan M Roden; Julie A Johnson; Stephen E Kimmel; Ronald M Krauss; Marisa Wong Medina; Alan Shuldiner; Russell A Wilke
Journal:  Circ Res       Date:  2011-09-16       Impact factor: 17.367

6.  Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.

Authors:  Sarah Baos; Wendy Underwood; Lucy Culliford; Barnaby C Reeves; Chris A Rogers; Ruth Bowles; Tom Johnson; Andreas Baumbach; Andrew Mumford
Journal:  Trials       Date:  2017-11-09       Impact factor: 2.279

7.  Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content.

Authors:  Y Shirasaka; A S Chaudhry; M McDonald; B Prasad; T Wong; J C Calamia; A Fohner; T A Thornton; N Isoherranen; J D Unadkat; A E Rettie; E G Schuetz; K E Thummel
Journal:  Pharmacogenomics J       Date:  2015-09-01       Impact factor: 3.245
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.